healthday.com

Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis

Blood Disorders

In a recent study, significantly more patients receiving the combination therapy met primary end point of reduction in spleen volume of ≥35 percent from baseline

pills medications

Adobe Stock

By:

Medically Reviewed By:

Farrokh Sohrabi, M.D.

Published on:

Updated on:

Mar 27, 2025, 3:41 pm

Loading content, please wait...

Journal

Prescription Drugs

Blood Cancer

Medication

Related Stories

No stories found.

© healthday-en 2025

Powered by Quintype

Read full news in source page